Keyword: JAMA

Merck CEO Kenneth Frazier worries new JAMA studies on pharma profitability ill exacerbate the ongoing political debate about drug pricing.

With a new JAMA study, Johnson & Johnson just got some new ammo for its defense against lawsuits claiming its talc products caused ovarian cancer.

The Trump proposal requiring pharma companies to add drug prices to advertising might not work according to plan.

Disease awareness advertising is soaring in the U.S., with the number of DTC campaigns growing to 401 from 44 over the past 20 years.

The balance of spending in medical marketing has shifted from almost 90% directed at healthcare professionals 20 years ago, to just 70%.

Soap operas often include medical mysteries and miracles, but some doctors are concerned about Incyte's connection to General Hospital's latest drama.

There is an expectation that biosimilars will reap billions of dollars in saving for U.S. consumers by 2020. But adoption could be slowed by a "rebate trap," two Yale medical experts say.

Years ago, teaching hospitals started raising hurdles to pharma reps. A few even barred salespeople at the door. They may have changed prescribing habits, too.

AbbVie’s former blockbuster AndroGel faces a class-action lawsuit over side effects—and a trial of a different sort as new testosterone-replacement data paint a mixed picture of the drug's safety.

Cancer drug websites load up on numbers about benefits, but tread lightly on side effects, an FDA study found. It’s the latest to flag weaknesses in cancer drug advertising and promotions.